Norman Eansor
Vermögen: 5 800 $ am 31.05.2026
Vermögen: 5 800 $ am 31.05.2026
Norman David Eansor is currently Chairman at Marker Therapeutics, Inc. since 2022, Director at B-MoGen Biotechnologies, Inc., and President at Cyvek, Inc. Former positions include President-Bioproducts Business Unit at Cambrex Corp.
in 2005, President-Protein Sciences Segment at Bio-Techne Corp.
from 2018 to 2022, Vice President-Pharmaceutical Operations at R.P.
Scherer Corp., President-Bioscience Division at Thermo Fisher Scientific, Inc. from 2010 to 2013, Vice President-Operations at Cardinal Health Corp.
in 2000, and Senior Vice President-Development & MD at Novus Biologicals LLC from 2013 to 2015.
Education includes undergraduate studies at the University of Western Ontario and an MBA from the University of Windsor.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.03.2026 | 3’694 ( 0.02% ) | 5 800 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Vorsitzender | 24.05.2022 |
B-MoGen Biotechnologies, Inc.
B-MoGen Biotechnologies, Inc. BiotechnologyHealth Technology Provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing | Direktor/Vorstandsmitglied | - |
CyVek, Inc.
CyVek, Inc. BiotechnologyHealth Technology Engages in the development of a novel, platform technology for measuring analytes in biological samples | Präsident | - |
| Unternehmen | Position | Ende |
|---|---|---|
| BIO-TECHNE CORPORATION | Corporate Officer/Principal | 03.01.2022 |
Novus Biologicals LLC
Novus Biologicals LLC Pharmaceuticals: MajorHealth Technology Develops and markets antibodies for scientific researchers | Corporate Officer/Principal | 01.01.2015 |
| THERMO FISHER SCIENTIFIC, INC. | Corporate Officer/Principal | 01.01.2013 |
| CAMBREX CORPORATION | Corporate Officer/Principal | 01.01.2005 |
Cardinal Health Corp.
Cardinal Health Corp. Medical DistributorsDistribution Services Manufactures and distributes hospital equipment | Geschäftsführer | 01.01.2000 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Cambrex Corp.
Cambrex Corp. Pharmaceuticals: GenericHealth Technology Develops and manufactures drug substances | Health Technology |
R.P. Scherer Corp.
R.P. Scherer Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures oral drug delivery systems | Health Technology |
Bio-Techne Corp.
Bio-Techne Corp. BiotechnologyHealth Technology Manufactures and sells biological products | Health Technology |
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
CyVek, Inc.
CyVek, Inc. BiotechnologyHealth Technology Engages in the development of a novel, platform technology for measuring analytes in biological samples | Health Technology |
University of Western Ontario
University of Western Ontario Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Windsor
University of Windsor Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets analytical and environment monitoring instruments | Health Technology |
Novus Biologicals LLC
Novus Biologicals LLC Pharmaceuticals: MajorHealth Technology Develops and markets antibodies for scientific researchers | Health Technology |
Cardinal Health Corp.
Cardinal Health Corp. Medical DistributorsDistribution Services Manufactures and distributes hospital equipment | Distribution Services |
B-MoGen Biotechnologies, Inc.
B-MoGen Biotechnologies, Inc. BiotechnologyHealth Technology Provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen